Why the study?
Does beta-blocker administration reduce major adverse cardiac events in Takotsubo syndrome patients with LVEF < 35%?
Design
Editorial
Key result
In patients with Takotsubo syndrome, LVEF < 35% on admission is a prognostic indicator for long-term outcomes, and beta-blocker therapy was associated with a lower incidence of major adverse cardiac events.
Authors
Loading...
LVEF <35% may stratify long-term TTS risk; hypothesis-generating and requires prospective validation before guiding care.
Does beta-blocker administration reduce major adverse cardiac events in Takotsubo syndrome patients with LVEF < 35%?
Severely reduced LVEF (<35%) is a strong prognostic indicator in Takotsubo syndrome, and beta-blocker therapy is associated with a lower incidence of major adverse cardiac events in this high-risk subgroup.
Yoshihiro J. Akashi (2019) conducted an editorial in Takotsubo syndrome (n=326). LVEF < 35% vs. LVEF > 35% was evaluated. In patients with Takotsubo syndrome, LVEF < 35% on admission is a prognostic indicator for long-term outcomes, and beta-blocker therapy was associated with a lower incidence of major adverse cardiac events.